A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs KLH 2109 (Primary)
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Acronyms EDELWEISS
  • Sponsors ObsEva
  • Most Recent Events

    • 15 Aug 2017 According to an ObsEva media release, enrollment in the European sites is complete while US recruitment remains ongoing. Completion of enrollment is expected in late 2017 or early 2018, with data expected from the first 12-week evaluation period around mid-2018.
    • 18 May 2017 According to an ObsEva media release, completion of enrollment of this trial is expected by the end of 2017, with data release planned 1H 2018.
    • 02 Mar 2017 Planned End Date changed from 1 Apr 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top